ESC 2022: DELIVER Demonstrates Benefits of Dapagliflozin in Heart Failure Regardless of Left Ventricular Ejection Fraction
Findings confirm the utility of SGLT2 inhibitors as foundational therapy for heart failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.